JANSSEN
19.7.2019 15:07:11 CEST | Business Wire | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2
The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1
“The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which are supported by the highest quality scientific evidence.”
The foundation of Janssen’s scientific understanding in prostate cancer is based on the knowledge acquired through the development of innovative treatment options for mCRPC. Abiraterone acetate is an oral androgen biosynthesis inhibitor that is approved for the treatment of both mCRPC and metastatic hormone-sensitive prostate cancer, in Europe.3,4
“The addition of abiraterone acetate to the Essential Medicines List is a significant milestone for Janssen Oncology, reflecting the tireless efforts in recent years to bring optimal treatment options to patients with mCRPC,” said Biljana Naumovic, Vice President Commercial Strategy Lead Oncology for Europe, Middle East & Africa, Cilag GmbH International. “This direction from the WHO further emphasises that our work is not yet over. It is critical that patients with prostate cancer have access to treatments that their clinicians feel can benefit them and that we continue to support the prostate cancer community in our common goal of making cancer a manageable and potentially one day, a curable condition.”
# ENDS #
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com/emea . Follow us at www.twitter.com/janssenEMEA for our latest news. Janssen-Cilag S.A. and Cilag GmbH International are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
About abiraterone acetate (ZYTIGA®
)
Abiraterone acetate plus prednisone/prednisolone is an approved therapy in mCRPC that inhibits production of androgens (which fuel prostate cancer growth) at all three sources that are important in prostate cancer - the testes, adrenals and the tumour itself.4,5,6
Abiraterone acetate is an oral therapy, taken in combination with prednisone/prednisolone for the treatment of:4
- newly diagnosed high risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)
- mCRPC in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated
- mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen
###
References
1
World Health Organisation. WHO updates global guidance on medicines and diagnostic tests to address health challenges, prioritize highly effective therapeutics, and improve affordable access. Available at https://www.who.int/news-room/detail/09-07-2019-who-updates-global-guidance-on-medicines-and-diagnostic-tests-to-address-health-challenges-prioritize-highly-effective-therapeutics-and-improve-affordable-access
. Last accessed July 2019.
2
World Health Organisation. World Health Organization Model List of Essential Medicines. Available at: https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?sequence=1&isAllowed=y
. Last accessed July 2019.
3
Bedoya DJ and Mitsiades N (2012). Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Expert Rev. Anticancer Ther. 12(1), 1–3.
4
European Medicines Agency. Zytiga Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_en.pdf
. Last accessed July 2019.
5
Hoy, SM. et al. Abiraterone Acetate: A review of its use in patients with metastatic castration-resistant prostate cancer drugs. Drugs 2013; 73:2077-2091.
6
Ritch, CR. Cookson, MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016 Oct 17;355:i4405. Doi: 10.1136/bmj.i4405.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190719005230/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Introduces Integrated Backend and Global Payment Solutions for Games, With Founding Partner AccelByte19.8.2026 15:00:00 CEST | Press release
Game Developers Can Now Apply For Early Access To The Integrated Solution Ahead Of Launch Xsolla, a global video game commerce company, today introduced integrated backend solutions for game developers through a founding partnership with AccelByte, a fully managed extensible games backend platform, and opened a closed testing program for a combined solution that pairs AccelByte Gaming Services (AGS) with Xsolla's global payments and monetization tools. Select developers can now apply for early access and help shape the integration ahead of its broader launch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819624666/en/ Graphic: Xsolla As studios scale live games across PC, mobile, console, and the web, managing player persistence, gaming backend, and global transactions adds cost and slows launches. Through the founding partnership with AccelByte, Xsolla brings AccelByte's backend services together with its own payments a
Corpay Cross-Border Named the Official FX Partner of European T20 Premier League19.8.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with the European T20 Premier League (“ETPL”), a new franchise-based tournament sanctioned by the International Cricket Council, created to establish Europe as a dynamic force in the global T20 landscape. Under the agreement, Corpay becomes EPTL’s exclusive and Official Foreign Exchange (FX) Partner, along with being an Official Partner. As the EPTL’s exclusive foreign exchange partner, Corpay Cross-Border will provide the league with comprehensive FX risk management solutions to help mitigate foreign exchange exposure arising from its day-to-day business activities. Corpay Cross-Border’s award-winning platform will also enable the EPTL to streamline global payments through a single point of access. “Corpay Cross-Border is thrilled to be named the exclu
Oscilloquartz expands US aerospace, defense and government presence to address rising demand for resilient PNT19.8.2026 14:00:00 CEST | Press release
News summary: Demand for resilient PNT solutions is rising across US aerospace, defense and government sectors as GNSS cyber threats increase New agreements with specialized US firms strengthen market access and customer engagement Expanded footprint supports delivery of mission-critical synchronization technologies across defense and government Oscilloquartz today announced an expansion of its US aerospace, defense and government presence through agreements with six specialized sales representative firms: ProTEQ Solutions, Southern Marketing Associates (SMA), Testech, TMS Sales, Contech Marketing Associates and Ward/Davis Associates. These partnerships expand regional coverage and deepen customer engagement, addressing growing demand for resilient timing and synchronization in mission-critical applications. “Demand for resilient timing and assured PNT continues to accelerate across aerospace, defense and government applications,” said Tim Weathers, president of Southern Marketing Asso
Bentley Systems Announces Finalists for the YII Awards 202619.8.2026 14:00:00 CEST | Press release
Prestigious annual awards program recognizes infrastructure professionals who use Bentley software in exceptional ways to drive real-world impact Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the finalists for its 2026 Year in Infrastructure (YII) Awards program. For more than two decades, the annual awards have celebrated infrastructure professionals and their innovative use of Bentley software to improve how infrastructure is designed, built, and operated. Selected by independent panels of global industry experts, this year’s finalists demonstrate how infrastructure professionals are leveraging technologies including digital twins and AI to deliver highly efficient project outcomes. In a review of the 36 finalist projects, 24 finalists reported using AI in some form, while 22 showed strong or supporting evidence of a connected digital foundation. “The YII Awards honor the professionals behind the infrastructure that comm
Xceedance Appoints Insurance and Technology Executive Adrian Spieler to Board of Directors19.8.2026 14:00:00 CEST | Press release
Xceedance, a global provider of technology-driven business solutions for the insurance industry, today announced the appointment of Adrian Spieler to its Board of Directors, effective immediately. Spieler brings more than 30 years of experience across reinsurance, insurance, and asset management to the Xceedance board. He has served as Chief Operating Officer at Convex Insurance, a leading specialty insurer and reinsurer, since its launch in 2019. Before Convex, he spent 17 years at Swiss Re in a series of senior leadership positions, and later served as Group Chief Administrative Officer at Catlin and as Chief Enterprise Operations Officer and Chief Platform Officer, Insurance, at XL Catlin. As a member of the Xceedance Board of Directors, he will provide strategic guidance, set organizational goals, and measure success as the organization continues its high-growth trajectory. “Technology-enabled transformation is reshaping the insurance and reinsurance industries,” said Spieler, “and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom